Division of Pulmonary and Critical Care and Sleep Medicine, Einstein Medical Center, Philadelphia, Pennsylvania.
Department of Medicine, Einstein Medical Center, Philadelphia, Pennsylvania.
Respir Care. 2021 Jun;66(6):897-908. doi: 10.4187/respcare.08319. Epub 2021 Jan 14.
The COVID-19 outbreak in the United States has disproportionately affected Black individuals, but little is known about the factors that underlie this observation. Herein, we describe these associations with mortality in a largely minority underserved population.
This single-center retrospective observational study included all adult subjects with laboratory-confirmed SARS-Cov-2 treated in our ICU between March 15 and May 10, 2020.
128 critically ill adult subjects were included in the study (median age 68 y [interquartile range 61-76], 45% female, and 64% Black); 124 (97%) required intubation. Eighty (63%) subjects died during their in-patient stay, which did not differ by race/ethnicity. Compared with other racial/ethnic groups, Blacks had a greater proportion of women (52% vs 30%, = .02) and subjects with hypertension (91% vs 78%, = .035). Asthma ( = .03) was associated with lower in-patient death, primarily among Black subjects ( = .02). Among Black subjects, increased age (odds ratio 1.06 [95% CI 1.05-1.22] per year), positive fluid balance (odds ratio 1.06 [95% CI 1.01-1.11] per 100 mL), and treatment with tocilizumab (odds ratio 25.0 [95% CI 3.5-180]) were independently associated with in-patient death, while higher platelets (odds ratio 0.65 [95% CI 0.47-0.89] per 50 × 10/mL) and treatment with intermediate dose anticoagulants (odds ratio 0.08 [95% CI 0.02-0.43]) were protective. Among other race/ethnic groups, higher total bilirubin (odds ratio 1.75 [95% CI 0.94-3.25] per 0.2 mg/dL) and higher maximum lactate (odds ratio 1.43 [95% CI 0.96-2.13] per mmol/L) were marginally associated with increased death, while tocilizumab treatment was marginally protective (odds ratio 0.24 [95% CI 0.05-1.25]). During first 72 h of ventilation, those who died had less increase in [Formula: see text] ( = .046) and less reduction in PEEP ( = .01) and [Formula: see text] requirement ( = .002); these patterns did not differ by race/ethnicity.
Black and other race/ethnicity subjects had similar mortality rates due to COVID-19 but differed in factors that were associated with increased risk of death. In both groups, subjects who died were older, had a positive fluid balance, and less improvement in [Formula: see text], PEEP, and [Formula: see text] requirement on ventilation.
美国的 COVID-19 疫情对黑人个体的影响不成比例,但人们对导致这一观察结果的因素知之甚少。在此,我们描述了这些与死亡率之间的关联,这是在一个主要由少数民族和服务不足的人群中进行的。
这是一项单中心回顾性观察研究,纳入了 2020 年 3 月 15 日至 5 月 10 日期间在我们 ICU 接受实验室确诊的 SARS-CoV-2 治疗的所有成年患者。
共纳入了 128 例危重症成年患者(中位年龄 68 岁[四分位间距 61-76],45%为女性,64%为黑人);124 例(97%)需要插管。在住院期间,80 例(63%)患者死亡,其死亡率与种族/民族无关。与其他种族/民族相比,黑人中女性比例较高(52% vs. 30%, =.02),高血压患者比例较高(91% vs. 78%, =.035)。哮喘( =.03)与住院死亡率降低有关,主要是在黑人患者中( =.02)。在黑人患者中,年龄每增加 1 岁(优势比 1.06[95%置信区间 1.05-1.22])、正液体平衡(优势比 1.06[95%置信区间 1.01-1.11]每 100 毫升)和使用托珠单抗(优势比 25.0[95%置信区间 3.5-180])与住院死亡率独立相关,而血小板计数较高(优势比 0.65[95%置信区间 0.47-0.89]每 50×10/mL)和使用中等剂量抗凝剂(优势比 0.08[95%置信区间 0.02-0.43])与死亡率降低有关。在其他种族/民族中,总胆红素较高(优势比 1.75[95%置信区间 0.94-3.25]每 0.2 毫克/分升)和最大乳酸较高(优势比 1.43[95%置信区间 0.96-2.13]每 mmol/L)与死亡率增加相关,而托珠单抗治疗有轻微保护作用(优势比 0.24[95%置信区间 0.05-1.25])。在通气的前 72 小时内,死亡患者的 [Formula: see text]( =.046)增加较少,PEEP( =.01)和 [Formula: see text]需求( =.002)减少较少;这些模式在种族/民族之间没有差异。
黑人及其他种族/民族的 COVID-19 死亡率相似,但与死亡率增加相关的因素不同。在这两个组中,死亡患者年龄较大,液体平衡为正,并且在通气期间 [Formula: see text]、PEEP 和 [Formula: see text]需求的改善较少。